Mittwoch, 04.11.2026, Calendar Week 45, 308. day of the year, 57 days remaining until EoY.

Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.

Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US44916K1060

Filter zurücksetzen

Do you already know our new terminal view? Click here.

FIGI: BBG00YVTN9J2

HYPR

Hyperfine, Inc.

GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Medical Devices

NAME

Hyperfine, Inc.

ISIN

US44916K1060

TICKER

HYPR

MIC

XNAS

REUTERS

HYPR.OQ

BLOOMBERG

HYPR US

Di., 03.11.2026 Hyperfine

Newsfeed

Hyperfine to Participate in Jefferies London and BTIG Tech-Enabled Healthcare Conferences | Hyperfine, Inc.

Hyperfine Advances International Swoop System Model 2 Rollout and Highlights the Role of Portable MRI in Brain Health Awareness | Hyperfine, Inc.

Hyperfine Reports Record Preliminary Third Quarter Revenue of Approximately $6.0 Million & Reaffirms Full Year 2026 Revenue Outlook of Approximately $20 to $22 Million | Hyperfine, Inc.

Hyperfine, Inc. to Announce Third Quarter 2026 Financial Results on November 9, 2026 | Hyperfine, Inc.

Hyperfine Expands Global Access to Portable Brain MRI Technology Across Key Gulf Cooperation Council Healthcare Markets | Hyperfine, Inc.

Hyperfine Announces Completion of Enrollment in the Contrast PMR Study to Support the Submission to Expand Indications for Use of the Swoop® System with Contrast Agents | Hyperfine, Inc.

Hyperfine, Inc. to Participate in Lake Street Capital Markets 10th Annual Best Ideas Growth Conference | Hyperfine, Inc.

Hyperfine Builds Momentum in Year One of Neurology Office Launch with NEURO PMR Publication and More Than 3,000 Scans | Hyperfine, Inc.

Hyperfine Announces FDA Clearance of the Next Optive AI™ Software, Further Enhancing Image Quality, Clinical Utility, and Ease of Use of the Swoop® System Across Care Settings | Hyperfine, Inc.

Hyperfine, Inc. Reports Second Quarter 2026 Financial Results | Hyperfine, Inc.

Hyperfine Announces the Release of Multiple Peer-Reviewed Publications, Expanding Clinical Evidence for the Swoop® System Across a Growing Number of Sites of Care | Hyperfine, Inc.

Hyperfine, Inc. to Announce Second Quarter 2026 Financial Results on August 6, 2026 | Hyperfine, Inc.

Hyperfine Announces European Launch of Next-Generation Swoop® System | Hyperfine, Inc.

Hyperfine Forms Global Neurosurgery Advisory Council to Support Expansion of Portable MRI in Neurosurgical Care | Hyperfine, Inc.

Hyperfine Swoop® System Scan Volume in the United States Hits Record Milestones Across Multiple Sites of Care | Hyperfine, Inc.

Hyperfine to Join Russell 2000® and Russell 3000® Indexes | Hyperfine, Inc.

Hyperfine Announces Presentation of Results from the PRIME Study Showing Portable MRI Substantially Reduces Time to Imaging in Emergency Departments | Hyperfine, Inc.

Hyperfine, Inc. Reports First Quarter 2026 Financial Results | Hyperfine, Inc.

Hyperfine Swoop® System Introduced as India’s First Portable MRI for Bedside Brain Imaging at the Country’s Leading Medical Institution | Hyperfine, Inc.

Hyperfine, Inc. to Announce First Quarter 2026 Financial Results on May 12, 2026 | Hyperfine, Inc.

Hyperfine Receives CE and UKCA Marks for Next-Generation Swoop® System and Latest Advancement in Optive AI™ Software | Hyperfine, Inc.

Hyperfine, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results | Hyperfine, Inc.

Hyperfine, Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026 | Hyperfine, Inc.

Hyperfine Announces Publication of Breakthrough Clinical Data Demonstrating the Swoop® System’s Enhanced Stroke Detection Capabilities | Hyperfine, Inc.

Hyperfine Announces NEURO PMR Study Results Showing High Diagnostic Value and Superior Patient Experience in Neurology Clinics | Hyperfine, Inc.

Hyperfine Announces Enrollment of First Patient in Study to Expand Intended Use of the Swoop® System with Contrast Agents | Hyperfine, Inc.

Hyperfine Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results | Hyperfine, Inc.

Hyperfine Announces First Peer-Reviewed Publication Demonstrating Significant Economic Benefits of Using the Swoop® AI-Powered Portable MRI System in Acute Hospital Care | Hyperfine, Inc.

Hyperfine Announces Regulatory Approval of the Swoop® System in India | Hyperfine, Inc.

Hyperfine Announces FDA Clearance of the First Optive AI™ Software Update with Advanced Diffusion Imaging Capability, Focused on Enhancing Stroke Detection with the Swoop® System | Hyperfine, Inc.

Hyperfine, Inc. to Participate in Upcoming Piper Sandler 37th Annual Healthcare Conference | Hyperfine, Inc.

Hyperfine Awarded $3.7 Million Grant to Advance Global Brain Health | Hyperfine, Inc.

Hyperfine, Inc. Reports Third Quarter 2025 Financial Results | Hyperfine, Inc.

Hyperfine, Inc. to Announce Third Quarter 2025 Financial Results on November 13, 2025 | Hyperfine, Inc.

Hyperfine Announces Pricing of $17.5 Million Public Offering | Hyperfine, Inc.

Hyperfine Announces Proposed Public Offering | Hyperfine, Inc.

Hyperfine Reports Preliminary, Unaudited Results for Third Quarter 2025, Signaling Strong Business Momentum Following the Launch of the Next Generation Swoop® System | Hyperfine, Inc.

Hyperfine Swoop® System Referenced in France’s Largest Public Hospital Procurement Body to Facilitate Nationwide Purchases of Portable MRI Technology | Hyperfine, Inc.

Hyperfine Launches PULSE Platform to Accelerate Adoption and Innovation of AI-Powered Portable MRI | Hyperfine, Inc.

Hyperfine Receives CE Mark and UKCA Approval for Optive AI™ Software, Expanding Global Commercialization of Latest AI-Powered Imaging Software | Hyperfine, Inc.

Hyperfine, Inc. to Participate in Upcoming Investor Conferences | Hyperfine, Inc.

Hyperfine Announces First Patients Enrolled in PRIME Study Aimed at Accelerating Adoption of AI-Powered Portable MRI in Emergency Departments | Hyperfine, Inc.

Hyperfine, Inc. to Announce Second Quarter 2025 Financial Results on August 13, 2025 | Hyperfine, Inc.

Hyperfine Swoop® AI-Powered Portable MRI System Demonstrates 100% Sensitivity for ARIA-E Detection in New Data Presented at the 2025 Alzheimer’s Association International Conference | Hyperfine, Inc.

Hyperfine Swoop® AI-Powered Portable MRI System Showcased in Clinical Studies Designed to Broaden Access to Dementia Care | Hyperfine, Inc.

Hyperfine Begins Commercial Launch of Optive AI™ Software, Bringing Substantially Improved Image Quality to the Installed Base of Swoop® Systems | Hyperfine, Inc.

Hyperfine Announces the First Commercial Sales of the Next-Generation Swoop® System Powered by Optive AI™ Software | Hyperfine, Inc.

Hyperfine Announces Key Executive Appointments to Strengthen its Leadership Position in AI-Powered Portable MRI | Hyperfine, Inc.

Hyperfine Announces FDA Clearance of a New Next-Generation Swoop® System Powered by Optive AI™ Software, Delivering a Transformative Leap in Image Quality | Hyperfine, Inc.

Hyperfine Announces FDA Clearance of Optive AI™ Software, Introducing the Most Substantial Image Quality Improvement Ever for the Swoop® System | Hyperfine, Inc.